FHTX
Foghorn Therapeutics Inc.
Key Financials
Operating Income
$-86389000
↑ 15.9%
EPS (Diluted)
$-1.18
↑ 25.3%
Revenue
$30.9M
↑ 36.8%
Total Assets
$198.1M
↓ 30.2%
Net Income
$-74283000
↑ 14.2%
Total Liabilities
$306.6M
↓ 7.0%
Shareholders' Equity
$-108500000.00
↓ 138.3%
Cash & Equivalents
$80.9M
↑ 45.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/14/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| SCHEDULE 13G/A | 5/6/2026 | View on SEC |
| ARS | 4/30/2026 | View on SEC |
| DEFA14A | 4/30/2026 | View on SEC |
| DEF 14A | 4/30/2026 | View on SEC |
| 8-K | 4/21/2026 | View on SEC |
| 4 | 4/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | FHTX |
| Company Name | Foghorn Therapeutics Inc. |
| CIK | 1822462 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-586-3100 |